Literature DB >> 34718958

Delivery strategies for cell-based therapies in the brain: overcoming multiple barriers.

Olivia M Turk1, Ryan C Woodall2, Margarita Gutova3, Christine E Brown4, Russell C Rockne2, Jennifer M Munson5.   

Abstract

Cell-based therapies to the brain are promising for the treatment of multiple brain disorders including neurodegeneration and cancers. In order to access the brain parenchyma, there are multiple physiological barriers that must be overcome depending on the route of delivery. Specifically, the blood-brain barrier has been a major difficulty in drug delivery for decades, and it still presents a challenge for the delivery of therapeutic cells. Other barriers, including the blood-cerebrospinal fluid barrier and lymphatic-brain barrier, are less explored, but may offer specific challenges or opportunities for therapeutic delivery. Here we discuss the barriers to the brain and the strategies currently in place to deliver cell-based therapies, including engineered T cells, dendritic cells, and stem cells, to treat diseases. With a particular focus on cancers, we also highlight the current ongoing clinical trials that use cell-based therapies to treat disease, many of which show promise at treating some of the deadliest illnesses.
© 2021. Controlled Release Society.

Entities:  

Keywords:  Blood–brain barrier; Brain; Cancer; Drug delivery; Neural stem cells; T cells

Mesh:

Year:  2021        PMID: 34718958      PMCID: PMC8987295          DOI: 10.1007/s13346-021-01079-1

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   5.671


  95 in total

1.  Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.

Authors:  Eric J Small; Paul F Schellhammer; Celestia S Higano; Charles H Redfern; John J Nemunaitis; Frank H Valone; Suleman S Verjee; Lori A Jones; Robert M Hershberg
Journal:  J Clin Oncol       Date:  2006-07-01       Impact factor: 44.544

2.  Dual role of ALCAM in neuroinflammation and blood-brain barrier homeostasis.

Authors:  Marc-André Lécuyer; Olivia Saint-Laurent; Lyne Bourbonnière; Sandra Larouche; Catherine Larochelle; Laure Michel; Marc Charabati; Michael Abadier; Stephanie Zandee; Neda Haghayegh Jahromi; Elizabeth Gowing; Camille Pittet; Ruth Lyck; Britta Engelhardt; Alexandre Prat
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-09       Impact factor: 11.205

3.  Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.

Authors:  Enli Liu; David Marin; Pinaki Banerjee; Homer A Macapinlac; Philip Thompson; Rafet Basar; Lucila Nassif Kerbauy; Bethany Overman; Peter Thall; Mecit Kaplan; Vandana Nandivada; Indresh Kaur; Ana Nunez Cortes; Kai Cao; May Daher; Chitra Hosing; Evan N Cohen; Partow Kebriaei; Rohtesh Mehta; Sattva Neelapu; Yago Nieto; Michael Wang; William Wierda; Michael Keating; Richard Champlin; Elizabeth J Shpall; Katayoun Rezvani
Journal:  N Engl J Med       Date:  2020-02-06       Impact factor: 91.245

4.  Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas.

Authors:  Timo M Kauer; Jose-Luiz Figueiredo; Shawn Hingtgen; Khalid Shah
Journal:  Nat Neurosci       Date:  2011-12-25       Impact factor: 24.884

5.  Effects of cervical-lymphatic blockade on brain edema and infarction volume in cerebral ischemic rats.

Authors:  Jinchao Si; Lianbi Chen; Zuoli Xia
Journal:  Chin J Physiol       Date:  2006-10-31       Impact factor: 1.764

6.  Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression.

Authors:  Khalid Shah; Emilie Bureau; Dong-Eog Kim; Katherine Yang; Yi Tang; Ralph Weissleder; Xandra O Breakefield
Journal:  Ann Neurol       Date:  2005-01       Impact factor: 10.422

Review 7.  Dendritic cell vaccines for brain tumors.

Authors:  Won Kim; Linda M Liau
Journal:  Neurosurg Clin N Am       Date:  2010-01       Impact factor: 2.509

8.  Effect of tissue permeability and drug diffusion anisotropy on convection-enhanced delivery.

Authors:  Wenbo Zhan; Ferdinando Rodriguez Y Baena; Daniele Dini
Journal:  Drug Deliv       Date:  2019-12       Impact factor: 6.419

9.  Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data.

Authors:  Prativa Sahoo; Xin Yang; Daniel Abler; Davide Maestrini; Vikram Adhikarla; David Frankhouser; Heyrim Cho; Vanessa Machuca; Dongrui Wang; Michael Barish; Margarita Gutova; Sergio Branciamore; Christine E Brown; Russell C Rockne
Journal:  J R Soc Interface       Date:  2020-01-15       Impact factor: 4.118

10.  Distinct migratory pattern of naive and effector T cells through the blood-CSF barrier following Echovirus 30 infection.

Authors:  Marie Wiatr; Carolin Stump-Guthier; Daniela Latorre; Stefanie Uhlig; Christel Weiss; Jorma Ilonen; Britta Engelhardt; Hiroshi Ishikawa; Christian Schwerk; Horst Schroten; Tobias Tenenbaum; Henriette Rudolph
Journal:  J Neuroinflammation       Date:  2019-11-21       Impact factor: 8.322

View more
  1 in total

Review 1.  Engineering in vitro immune-competent tissue models for testing and evaluation of therapeutics.

Authors:  Jennifer H Hammel; Jonathan M Zatorski; Sophie R Cook; Rebecca R Pompano; Jennifer M Munson
Journal:  Adv Drug Deliv Rev       Date:  2022-01-11       Impact factor: 15.470

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.